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Background: Prednisolone was one of the first glucocorticoids to be synthesised, but it is still widely applied to
cattle. Illegal uses of prednisolone include its uses for masking a number of diseases before animal sale and, at
lower dosages for extended periods of time, for the improvement of feed efficiency and carcass characteristics.
Since occasional presence of prednisolone has been detected at trace level in urine samples from untreated cattle,
the Italian Ministry of Health introduced a provisional limit of 5 ng/mL to avoid false non-compliances. However,
this limit proved ineffective in disclosing prednisolone misuse as a growth-promoter. In the present study, prednisolone
acetate was administered to finishing bulls and cows according to a therapeutic protocol (2 × 0.4-0.5 mg/kg bw
i.m. at 48 h interval) to further verify the practical impact of this cut-off limit and develop sound strategies to
distinguish between exogenous administration and endogenous production. Urinary prednisolone, prednisone,
20β-dihydroprednisolone, 20α-dihydroprednisolone, 20β-dihydroprednisone, 6β-hydroxyprednisolone, cortisol,
and cortisone were determined using a validated LC/MS-MS method.
Results: The urinary excretion profile showed the simultaneous presence of prednisolone, 20β-dihydroprednisolone,
and prednisone, the latter at lower concentrations, up to 33 days after the first dosing. Higher analyte levels were
detected in bulls even after correction for dilution in the urine. Prednisolone concentrations below 5 ng/ml were
determined in half of the samples collected at 19 days, and in all the samples obtained 26 and 33 days after the first
administration. No measurable concentrations of prednisolone or its metabolites were found in the samples collected
before the treatment, while cortisol and cortisone levels lower than the respective LOQs were observed upon treatment.
Conclusions: The present study confirms the criticism of the coarse quantitative approach currently adopted to
ascertain illegal prednisolone administration in cattle. As previously shown for growth-promoting treatments of
meat cattle, the simultaneous determination of urinary prednisolone, prednisone, 20β-dihydroprednisolone, along
with cortisol and cortisone, may represent a more reliable approach to confirm the exogenous origin of prednisolone.
Such a strategy would facilitate unequivocal detection of animals treated with prednisolone acetate using a therapeutical
protocol, even 3 to 4 weeks after the treatment.
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Synthetic glucocorticoids are extensively employed in cat-
tle therapeutic treatments due to their well recognized
anti-inflammatory, anti-allergic, and metabolic properties.
They are used in the treatment of primary ketosis, disor-
ders of the musculoskeletal system, allergic reactions, skin
diseases, and shock [1]. Despite its relatively low gluco-
corticoid potency in comparison with synthetic fluorinated
derivatives (e.g. dexamethasone, betamethasone, flumetha-
sone or isoflupredone), prednisolone is still widely used in
cattle, including dairy cows, particularly for its effective-
ness in the treatment of mastitis, in conjunction with anti-
microbial drugs [2,3].
Besides therapeutic applications, synthetic glucocorti-
coids (including prednisolone) are being increasingly
used illegally as growth promoters in veal calves, finish-
ing bulls and possibly old cows at the end of their pro-
ductive cycle, giving rise to a relatively high incidence of
non compliances [4]. Significant live weight increase,
coupled with an improvement of both feed conversion
and carcass quality traits [5,6], have been reported in
treated animals, as the result of several pharmacological
mechanisms, including gene modulation at muscle level
[7]; in this case, the oral route is usually preferred, and
involves the administration of low dosages for an ex-
tended period of time. As for most glucocorticoids,
growth-promoting effects have been demonstrated for
prednisolone, orally administered as its acetate ester in
beef cattle (15–30 mg per capita/day) for 30–35 days
[8,9]. In addition, prednisolone is also likely to be ad-
ministered to hide traumatic pathologies just before the
animal sale, or to speed up the drying-off period in dairy
cows, a well-known side effect of glucocorticoids, which
is linked to both the inhibition of peripheral glucose
utilization and the effects on water and electrolyte balance
brought about by such drugs [10,11]. In either case, the
treatment is seldom recorded officially and, consequently,
appropriate withdrawal periods are rarely applied.
To protect the consumer’s health, Maximum Residue
Limits for prednisolone have been set for bovine meat,
liver, kidney, fat, and milk [12]. In the absence of an offi-
cial record of the treatment, the occurrence of measur-
able levels of the drug in urine samples collected at the
farm or the slaughterhouse is considered to reflect the
misuse or abuse of this glucocorticoid [13].
Recently, evidence has been provided that veal calves
and cows, under heavy stress conditions, would produce
endogenous prednisolone, resulting in the presence of
trace amounts of the glucocorticoid in the urine together
with remarkable levels of cortisol and cortisone [14].
The structural affinity between cortisol and prednisolone
has raised the hypothesis that the latter could originate
from the former. Moreover, the occurrence of prednisol-
one was demonstrated in bovine adrenals and otherorgans from untreated cattle [15,16]. However, neither
the tissue(s) nor the metabolic pathway(s) involved in
the alleged endogenous synthesis of prednisolone has
been clarified yet.
To avoid false non-compliances, a provisional limit of
5.0 ng/mL for prednisolone in cattle urine was estab-
lished in 2012 by the Italian Ministry of Health, in agree-
ment with a suggestion of the European Union Reference
Laboratory [17]. However, previous studies revealed that
the oral dosing of beef cattle with prednisolone acetate ac-
cording to a growth-promoting protocol never resulted in
prednisolone concentrations higher than 1 ng/mL in urine
specimens collected during the treatment [8,18]. There-
fore, the current 5.0 ng/mL limit is likely to generate false
negative results, with the potential for the exposure of
consumers to harmful residues. On the other hand, only
scant data are presently available to assess the practical
impact of the provisional prednisolone urinary limit of 5.0
ng/mL in cattle undergoing a pharmacological treatment
with the glucocorticoid [19].
The main aims of the present study were to character-
ise the urinary excretion profile of prednisolone after
intramuscular (i.m.) administration to healthy finishing
bulls and cows using a therapeutic schedule and the ap-
plicability of the 5.0 ng/mL urinary limit to such animals.
Moreover, in agreement with the approach followed for
bullocks administered with a growth-promoting protocol
[18], the urinary concentrations of cortisol, cortisone,
prednisone, and of further prednisolone metabolites were
also determined with the aim to develop an appropriate
interpretation strategy to distinguish the urinary presence
of exogenous prednisolone from that related to the alleged
endogenous synthesis .
Methods
Animals, treatments, and sample collection
The study was conducted on eight Charolais finishing
bulls (average weight of about 400 kg) and six Friesian
non-lactating cows at the end of their productive cycle
(average weight of about 500 kg). The experimental plan
was designed according to the guidelines of the Italian
law for care and use of experimental animals [20], and
the study was approved by the Ministry of Health and
the local Committee for Animal Welfare. The animals
were clinically healthy and bred with a standard diet.
After an acclimatization period of one week (Figure 1),
they were subjected to a first urine sampling (T = −7)
and after a further week to a second one (T = 0) just be-
fore being i.m. treated with prednisolone acetate at the
maximum recommended dosage for cattle. To mimic
conditions usually applied by the practitioners, all indi-
viduals received 14 mL of a commercial preparation
(Novosterol®, Ceva Vetem SPA, Italy) containing 15 mg
prednisolone acetate/mL suspension, corresponding to
Figure 1 Treatment schedule and urine collection. Finishing bulls and cows were treated i.m. according to a therapeutical protocol (2 × 0.4-0.5 mg
prednisolone acetate/kg body weight at 48 h interval). Urine was collected at the indicated timepoints up to 33 days after the first administration.
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mg/kg body weight, for bulls and cows, respectively). A
second dosing was performed after 2 days (T = 2). Urine
sampling (spontaneous micturition) was also performed
1, 2, 3, 4, 6, 8, 10, 12, 19, 26, and 33 days after the first
treatment, respectively, usually late in the morning (11 a.
m.). After collection, urine specimens were immediately
stored at −20°C pending their analysis.Chemicals and reagents
Diethylether and acetonitrile were supplied by Sigma–
Aldrich (St. Louis, MO, USA). Sodium hydroxide and
hydrochloric acid were purchased from Carlo Erba Reagenti
(Milan, Italy). β-glucuronidase/aryl-sulfatase was from Roche
Diagnostics (Mannheim, Germany). 20α-dihydroprednisolone,
20β-dihydroprednisolone, 6β-hydroxyprednisolone and
20β-dihydroprednisone were supplied by Steraloids (Newport,
RI, USA). Prednisone, prednisolone, and cortisol were
purchased from Sigma Aldrich (Milan, Italy). Triamcin-
olone acetonide-d6 (internal standard (IS)) was from
RIVM (Bilthoven, The Netherlands). Stock standard solu-
tions of all the analytes were prepared in acetonitrile at a
concentration of 1 mg/mL and stored at −20°C in the dark.Sample preparation and instrumental analysis
The analytical method adopted for the determination of
corticosteroids and metabolites, along with the figures of
merit resulting from the validation process were re-
ported in previous studies [18,21]. Briefly, urine samples
were subjected to a liquid/liquid extraction at pH 8.5–
9.5 with diethylether after β-glucuronidase/arylsulfatase
deconjugation. After centrifugation, the supernatant or-
ganic phase was transferred into a 10-mL glass tube and
evaporated to dryness under nitrogen at 40°C. The resi-
due was re-dissolved in 50 μL of H2O/CH3CN (70/30)
mixture and transferred into an analytical vial for the
instrumental analysis, performed with a LC-MS/MS ap-
paratus. An Agilent 1100 series liquid chromatograph
(Agilent Technologies, Palo Alto, CA, USA), was inter-
faced to an Applied Biosystems API 4000 triple quadrupole
mass spectrometer (Applied Biosystems Sciex, Ontario,
Canada), operating in atmospheric pressure chemical ion-
isation positive ion mode.The essential parameters and figures of merit of the
latter analytical method are reported in Table 1.
Validation of the methods was not performed accord-
ing to the Commission Decision 2002/657/EC for all the
analytes. Since only prednisolone and prednisone are
included in official monitoring plans, CCα has been de-
termined only for these two analytes. For the other
prednisolone/prednisone metabolites, and for cortisol
and cortisone as well (both included into the method in
a second time) a simpler validation approach was car-
ried out, with LOD calculation only.
All urine samples were analyzed with the method ini-
tially developed for prednisolone, prednisone, cortisol,
and cortisone [21]. Later on, after the new analytical
method for the entire set of metabolites was developed
and validated [18], the residual urine samples were ana-
lyzed once more for the presence of metabolites and cre-
atinine (see 2.4). The stable concentrations of prednisolone
and prednisone proved that the residual samples remained
unchanged during storage at −20°C and despite the single
freeze-and-thaw cycles intervened. For the reasons out-
lined above, a complete set of samples was no longer avail-
able; the residual urine volumes allowed the analysis to be
performed on the majority of bull and cow specimens col-
lected 0, 1, 3, 19, and 33 days after the first administration.
Scattered data at different time points on a reduced set
of individuals were also available, but they did not
change the interpretation of the results, so they have
not been reported. All the raw data concerning prednis-
olone, prednisone, and the measured metabolites, upon
which the following discussion is based, are available as
an additional file (Table T1-T6 in “Additional file 1”).
Determination of creatinine
Creatinine is an endogenous by-product of muscle activ-
ity, which is produced with limited intra-day variation in
a given individual and cleared at a constant rate by the
kidney. Therefore, it has been long used to normalize
urinary values of certain analytes (e.g. cortisol) to ac-
count for individual hydration and time since last urin-
ation [22,23]
Urinary creatinine was measured using two methods, a
creatinine assay by ARCHITECT C8000 System (Abbott,
Abbott Park, IL, USA) and a LC-MS/MS method [24].
Table 1 Essential parameters and figures-of-merit of the analytical method adopted for determination of cortisol,
cortisone, prednisolone and some of its metabolites
Analyte Retention time (min) Precursor ion m/z Product ions CCα (ng/mL) LOD (ng/mL)
6β-hydroxyprednisolone 4,3 377.3 377.3➔341.2 Q – 0.41
377.3➔323.2
377.3➔359.3
20α-dihydroprednisolone 10.5 363.3 363.3➔267.4 Q – 0.36
363.3➔291.3
363.3➔309.3
20β-dihydroprednisolone 11.6 363.3 363.3➔345.2 Q – 0.35
363.3➔267.3
363.3➔291.3
20α-dihydroprednisone 12.3 361.3 361.3➔153.2 Q – 0.42
361.3➔297.3
361.3➔313.2
Prednisolone 17.1 361.3 361.3➔279.2 Q 0.67 0.05
361.3➔265.2
361.3➔223.2
Prednisone 17.9 359.3 359.3➔313.2 Q 0.66 0.05
359.3➔295.2
359.3➔267.2
Cortisol 17,7 363.2 363.2➔121.3 Q – 0.1
363.2➔147.3
363.2➔309.4
Cortisone 18.9 361.2 361.2➔163.4 Q – 0.1
361.2➔121.3
361.2➔105.3




***LOD: Limit of Detection.
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creatinine and sodium picrate to form a creatinine-picrate
complex. The rate of increase in absorbance at 500 nm
due to the formation of this complex is directly propor-
tional to the concentration of creatinine in the sample.
Since the creatinine kit is proposed for the quantitation of
creatinine in human serum, plasma or urine and not for
bovine urine, ten samples (out of 56, tested with the cre-
atinine kit) were analysed also by means of LC-MS/MS.
No substantial differences were found between the two
sets of results.
The LC-MS/MS apparatus was the same employed for
prednisolone and its metabolites determination, but with
an electrospray ionization source (ESI), operating in
positive ion mode. The MS parameters were set as fol-
lows: curtain gas: 10 psi; ion source gas-1: 40 psi; ion
source gas-2: 40 psi; ion spray voltage: 5000 V; probetemperature:350 C; declustering potential: 31 V; en-
trance potential: 10 V. Three transitions of parent ion to
product ion were considered (114.0➔ 44.2; 114.0➔ 86.1;
114.0➔ 72.0). Their optimal values of collision energy
and collision cell exit potential were: CE = 29 V and
CXP = 6 V for product ion 44.2; CE = 16 V and CXP = 15
V for product ion 86.1; CE = 22 V and CXP = 12 V for
product ion 72.0.
The LC system was equipped with a Phenomenex Luna
HILIC column (100 × 4.6 mm, 3 m) and a Phenomenex
SecurityGuard 4.0 mm× 2.0 mm pre-column. The chro-
matographic run was carried out using a binary mobile
phase of 0.1% HCOOH in highly purified water (A) and
acetonitrile (B), under the following program: isocratic
condition of 50% acetonitrile for 2 min; linear gradient
from 50% to 10% acetonitrile in 5 min; isocratic with 10%
acetonitrile for 1 min; linear gradient from 10% to 50%
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volume was 10 μL and the flow rate was 0.4 mL/min.
Statistics
Where appropriate, statistical differences were evaluated
by Student’s t-test with GraphPad InStat version 3.00
(GraphPad Software, San Diego, CA, USA) at a 5% sig-
nificance level (P < 0.05).
Results
Kinetics of prednisolone and prednisone urinary excretion
in finishing bulls and cows
Figure 2 displays the profile of prednisolone and pred-
nisone urinary excretion in treated bulls and cows.
Neither compound could be detected in any urine speci-
men collected before drug dosing in cattle of either sex.
In finishing bulls (Figure 2A), the urinary prednisolone
concentration peaked 24 hours after the second adminis-
tration (T = 3) with an average level of 72 ng/mL, showing
a progressive decline thereafter, with average concentra-
tions between 40 and 60 ng/mL until T = 12, i.e. 10 days
after the second injection. Measurable prednisolone levelsFigure 2 Urinary excretion profile of prednisolone and prednisone
in finishing bulls and cows i.m. treated with prednisolone acetate.
Finishing bulls and cows were treated i.m. with the glucocorticoid with a
therapeutical dosage at T = 0 and T = 2. A) finishing bulls (n = 8); B) cows
(n = 6). Figures under or over the graph symbols at T = 26 and T = 33
indicate the number of animals exhibiting measurable values (>CCα).
Further information may be found in the supplementary files.(>CCα) were detected in all animals at T = 19 and T = 26
and in four out of eight individuals at T = 33, correspond-
ing to 31 days after the second administration. For four
out of eight urine samples collected at T = 19, and all
those obtained at both T = 26 and T = 33, prednisolone
concentration was below 5 ng/mL. Prednisone was already
detectable 24 hours after the first administration (T = 1);
its concentration peaked at T = 3 (around 27 ng/mL) exhi-
biting a slow decrease thereafter, corresponding to average
concentrations of about 9 ng/mL at T = 12 and 1 ng/mL
at T = 19. Levels of prednisone lower than 1 ng/mL but
higher than the CCα could be detected at T = 26 and T =
33 in two and one individuals, respectively.
For cows (Figure 2B), the highest prednisolone con-
centrations were observed in urine samples collected 24
hours (T = 1) and 96 hours (T = 4) after the first dosing,
with average values of 22 and 21 ng/mL, respectively. A
slow decline was subsequently observed, with concen-
trations ranging between 9 and 11 ng/mL; at T = 19
and T = 26, three and five out of six animals, respect-
ively, displayed urinary concentrations above the CCα,
but lower than 5 ng/mL. Thirty-three days after the
first administration, low but still measurable amounts
of the drug could be detected in two urine samples.
Prednisone was already detectable 24 hr after the first
administration, at concentrations that remained within
a constant range (between approximately 2 to 4 ng/mL)
throughout most of the collection period. At T = 26
and T = 33 prednisone concentrations around 1 ng/mL
were measured for four and one animals, respectively.Urinary cortisol, cortisone, and metabolites of prednisolone
and prednisone in prednisolone-treated finishing bulls and
cows
The presence of the main prednisolone and prednisone me-
tabolites, plus cortisol and cortisone was investigated in
urine samples collected 0, 1, 3, 19, and 33 days after the first
drug treatment, respectively. In both finishing bulls and
cows, 20β-dihydroprednisolone, 20α-dihydroprednisolone,
20β-dihydroprednisone, 6β-hydroxyprednisolone, and corti-
sone were not detected (<LOD) in any urine sample col-
lected before the first administration (T = 0). Cortisone
remained undetectable (<LOD) in any specimen collected
from bulls and cows after treatment (T = 1, T = 19, T = 33).
Cortisol concentration was below the LOQ value in all
urine samples collected from cows, whereas it could be de-
termined in urine samples collected from five finishing bulls
before any treatment (T = 0) at low ppb level (1.17 ng/mL,
0.92 ng/mL, 0.63 ng/mL, 1.26 ng/mL and 3.44 ng/mL, for
animals A, B, C, D and H, respectively) and in samples
from three individuals collected 31 days after the first
administration (T = 33; 1.14 ng/mL, 0.90 ng/mL and
1.23 ng/mL, for animals A, C and D, respectively).
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graphic profiling of the metabolites detected in urine
samples from a bull (Bull A) 24 hours after the first i.m.
dosing with prednisolone.
Measurable amounts (>LOQ) of 20β-dihydroprednisolone,
20α-dihydroprednisolone, 20β-dihydroprednisone, and
6β-hydroxyprednisolone were detected in all urine sam-
ples from finishing bulls (Figure 4A), collected both 1
and 3 days after the first prednisolone treatment, while
at T = 19 (i.e. 19 days after the first dosing), only 20β-
dihydroprednisolone reached measurable levels in urine sam-
ples from all individuals. At T= 33, 20β-dihydroprednisolone
and 20β-dihydroprednisone levels higher than LOQ still
occurred in four and five individuals, respectively. In gen-
eral, average concentrations of 20β-dihydroprednisolone
(at all timepoints) and further metabolites (whenever de-
tectable) were of the same order of magnitude as the par-
ent drug or even higher (e.g. 20β-dihydroprednisolone at
T = 3 and 20β-dihydroprednisone at T = 19 and T = 33).
In the urine samples obtained from cows (Figure 4B),
20β-dihydroprednisolone was the only metabolite that
could be found in all animals at T = 1, T = 3, and T = 19,
and in three out of six individuals at T = 33, always reach-
ing concentrations similar to those of the parent drug. In
general, 20α-dihydroprednisolone, 20β-dihydroprednisone,
and 6β-hydroxyprednisolone exhibited measurable values
shortly after drug administration (T = 1, T = 3), while in
samples collected after 19 and 33 days periods, these me-
tabolites could be detected only in few animals.Figure 3 Chromatographic profiles of a sample (from bull A) collected
therapeutic schedule. Unmodified prednisolone and all the five metaboli
(6β-hydroxyprednisolone) to 63,5 ng/mL (20β-dihydroprednisolone).Urinary creatinine in finishing bulls and cows
Creatinine levels in urine samples collected at T = 0, T = 3,
T = 19, and T = 33 are reported in Table 2. While higher
creatinine average values were recorded for bulls with re-
spect to cows, statistically significant differences occurred
at T = 3 and T = 19 only.Discussion
Despite the extensive legal use of prednisolone in bovine
clinical practice and the documented potential for its
abuse and misuse, only scant information is available
concerning the excretion profile of this glucocorticoid in
cattle urine, which is the matrix of choice for the official
control in living animals in the large majority of the EU
Member States [25]. The only available study was carried
out in an international interlaboratory comparison test
[19]: an average value of 1.58 ng/mL was reported in urine
specimens from two “bovines” (140–150 kg) collected 24
hours after a single i.m. administration of 30–32 mg “pred-
nisolone” (unspecified nature), equivalent to 0.2 mg/kg
b.w.. In the present study, higher urinary prednisolone
concentrations were found at about the same timepoint
in bulls and cows administered with 0.4-0.5 mg/kg b.w.
prednisolone dosages, corresponding to a typical thera-
peutical schedule for adult cattle (2 × 210 mg prednisolone
acetate/head at a 24 hr interval). The different ages, dos-
ages and administration protocols make it impossible any
close comparison.1 day after the first prednisolone administration using a
tes are present at noticeable concentrations, ranging from 7,59 ng/mL
Figure 4 Urinary excretion profile of prednisolone, prednisone and selected metabolites in finishing bulls and cows i.m. treated with
prednisolone acetate. Finishing bulls and cows were treated i.m. with the glucocorticoid with a therapeutical dosage. A) finishing bulls (n = 8);
B) cows (n = 6). Figures over the bar symbols indicate the number of animals exhibiting measurable values (>CCα or > LOQ). n.d. = not detectable;
n.a = not available. Further information may be found in the supplementary files.
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ered for surveillance purposes is hair. Thanks to bio-
accumulation of many analytes, including steroids, the
hair matrix allows their prolonged detectability. It has
been used in forensic analysis and may be a matrix of
choice also for long-term corticosteroid misuse deter-
mination in cattle [26,27]. However, it is not considered
an official matrix for corticosteroids in Italy, and no in-
formation is available concerning the accumulation of
prednisolone in cattle hair.
In the present investigation, the urinary excretion pro-
file of prednisolone, i.m. injected to finishing bulls and
cows, was characterized by a peak in the 24–48 hr
period after each administration, followed by a relatively
slow decline, with measurable levels of the drug in sam-
ples collected 26 days (all individuals) and even 33 days
(4 bulls and 3 cows) after the first administration. These
results are consistent with the slow absorption half-life
(48 h), the long persistence of measurable levels inTable 2 Urinary creatinine levels (mg/mL) at different
timepoints in finishing bulls and cows treated
intramuscularly with prednisolone acetate (therapeutical
schedule)
Time (days after the
first treatment)
Finishing bulls Cows Ratio
0 1.4 ± 0.28a 0.93 ± 0.22a 1.50
3 2.0 ± 0.21a 0.54 ± 0.18b 3.70
19 1.5 ± 0.13a 0.86 ± 0.24b 1.74
33 1.3 ± 0.27a 0.73 ± 0.16a 1.78
Values represent mean ± SEM; rows with different superscripts (a or b) are
statistically significant different (P < 0.05).serum, and the prolonged glucocorticoid action already
reported in cows administered i.m. with a suspension of
prednisolone acetate at a comparable dosage [28,29]. For
comparison, it is worth noting that the i.m. administration
of dexamethasone sodium phosphate to finishing bulls
using a therapeutic schedule (60 μg/kg b.w./day for 3 con-
secutive days) resulted in rapid urinary excretion, so that
no detectable concentrations of the drug could be found
as early as four days from the first injection [30].
Among synthetic glucocorticoids, prednisolone has the
unique property to bind specifically and with high affin-
ity to plasma corticosteroid binding globulin [31]. This
and other factors may explain the sharp differences in
the urinary excretion profiles between prednisolone
acetate and dexamethasone sodium phosphate. While
acetate esters are known to be hydrolyzed more slowly
than phosphates [32], fluorinated glucocorticoids such
as dexamethasone are quite refractory to oxidative, re-
ductive and conjugative biotransformations in cattle
and other ruminants [30,33,34] , so that they are mainly
excreted unmodified in the urines. This is not the case
for prednisolone: several studies indicate that in mamma-
lian species including cattle [35,36], 11β-hydroxysteroid-
dehydrogenases (11β-HSD) mediate the interconversion
of glucocorticoids usually favouring the more active 11-
hydroxy-compound over the 11-keto-metabolite. Accord-
ingly, our investigation confirms the rapid appearance and
persistence of the reduced metabolite prednisone in the
bovine urine with average concentrations 2− to 7 − fold
lower than prednisolone throughout the monitoring time.
It is not known to what extent the interconversion of
prednisolone and prednisone may contribute to the slow
excretion of the parent drug and its precursor/metabolite.
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namely 20β-dihydroprednisolone, 20α-dihydroprednisolone,
20β-dihydroprednisone, and 6β-hydroxyprednisolone, had
been previously identified in the urine specimens collected
from a bullock treated i.m. with prednisolone acetate at the
same dosage used in this trial [18]. A similar metabolic pro-
file had been reported in humans, where the 20α- and the
20β-reduced derivatives were allegedly generated by two hy-
droxysteroid dehydrogenases, namely 20α-hydroxysteroid
dehydrogenase and 3α,20β-hydroxysteroid dehydrogenase
[37], while the hydroxylated metabolite was synthesized
by cytochrome P450 3A4 [38]. In the study mentioned
above [18], finishing bulls, treated according to a
growth-promoting protocol, exhibited urinary levels of
20β-dihydroprednisolone largely exceeding those of the
parent drug, while none of the remaining metabolites
could be detected. In the present study, finishing bulls
and cows dosed with a pharmacological schedule exhib-
ited a sharply different excretion profile in which pred-
nisolone, prednisone, and 20β-dihydroprednisolone
were consistently recorded at similar concentrations for
all animals during and immediately after the treatment,
as well as 19 days after the first administration. In addition,
20α-dihydroprednisolone, 20β-dihydroprednisone, and 6β-
hydroxyprednisolone were detected in the urine samples
collected from a limited number of animals at 19 and 33
days after the first administration, although their concen-
trations were lower than those of the parent drug and its
major metabolites.
Data from this study indicate that the average urinary
concentration of both prednisolone (1.5− to 7 − fold)
and prednisone (1− to 10 − fold) was consistently higher
for finishing bulls than for cows at timepoints up to 19
days after the first administration. A similar trend was
also observed for the other metabolites. Such a differ-
ence may be partly explained by the slightly higher drug
dosage received by the bulls with respect to their body
weight (0.5 vs. 0.4 mg/kg bw) and the larger dilution of
cow urines, as inferred from their lower creatinine levels
(1.5− to 3.7 − fold, at the same timepoint). However,
other factors may have also played a role, including gender
differences in the basal expression and/or glucocorticoid-
mediated modulation of 11β-HSD [39] or other enzymes
(e.g. CYP3A) involved in the generation of the examined
prednisolone metabolites [40,41].
As mentioned before, the Italian Ministry of Health
has recently enacted a provisional limit of 5 ng/mL for
urinary prednisolone in bovine species to account for
any possible “endogenous” synthesis. Such a high limit
already prevented the disclosure of prednisolone abuse
as a growth-promoter in beef cattle, since the prednisol-
one urinary concentration remained largely below the
cut-off limit for all treated animals throughout the whole
experimental period [8], thus generating “false compliances”to the law requirements. According to data obtained in the
present study, the therapeutic administration of prednisol-
one acetate to cattle would not result in “false compliances”
only for urine samples collected from bulls and cows close
to dosing or in the 10–12 days thereafter. Indeed, the appli-
cation of the 5 ng/mL limit would have classified as compli-
ant about half of the samples collected at T = 19 and all
samples obtained at both T = 26 and T = 33. Even more
striking is the case of urine samples T = 26 and T = 33 of a
cow (identified with “C”) that contain prednisolone concen-
trations below 5 ng/mL (4.67 ng/mL and 2.26 ng/mL, re-
spectively) and prednisone concentrations above the CCα
(2.19 ng/mL and 0.65 ng/mL, respectively), thus being com-
pliant for the administered drug, but non-compliant for its
ketonic metabolite, which is considerably less abundant.
All these irrational conclusions confirm the need of
adopting a radically different approach to legally dis-
criminate between exogenous administration of prednis-
olone and its alleged endogenous origin in cattle. One
point that should be taken into account is that the heavy
stress condition, supposedly generating endogenous pro-
duction of prednisolone, usually entails an increase in
urinary concentrations of cortisol and cortisone [14-16],
whereas the exogenous administration of prednisolone is
likely to depress the synthesis and hence the urinary ex-
cretion of these endogenous glucocorticoids [28]. In this
respect, it is worth noting that in cows we found urinary
concentrations of cortisol and cortisone lower than their
respective LOQs both before and after prednisolone dos-
ing, while measurable levels of cortisol only could be de-
tected in a few bulls at both T = 0 and T = 33, i.e. prior
to treatment and 31 days after the last administration,
respectively.
Conclusion
Several pieces of evidence potentially highlighting the
occurrence of prednisolone abuse (e.g. failure to comply
with the withdrawal time, masking of an existing path-
ology, use in lactating cows to speed up the drying off
period) may be derived from the urinary excretion profiles
emerging from this study involving a typical pharmaco-
logical treatment of adult cattle with prednisolone acetate
(2 × 0.4-0.5 mg/kg bw i.m. at a 48 h interval). Characteris-
tic features of these profiles are: i) the regular presence of
prednisolone and prednisone, the latter usually at lower
concentration, even after three to four weeks after the first
dosing, ii) the very low cortisol and cortisone levels at any
checked timepoint, iii) the consistent occurrence of
20β-dihydroprednisolone and, more sporadically, other
reduced or oxidized metabolites of prednisolone and
prednisone, and iv) the absence of measurable concen-
trations (<CCα/LOQ) of prednisolone, prednisone and
any other prednisolone metabolite before the treatment.
Our findings also indicate that the merely quantitative
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tion for the parent drug - prednisolone - in urine) does
not appear to be adequate to ascertain the illicit exposure
of cattle to prednisolone according to both a growth-
promoting schedule [8] and, as assessed here, also to a
therapeutic treatment, at least after 3 to 4 weeks after
treatment discontinuation. A more biologically-oriented
strategy involving the simultaneous determination of urin-
ary cortisol and cortisone, together with prednisolone,
prednisone and at least 20β-dihydroprednisolone among
metabolites, is likely to represent a more effective approach
for surveillance purposes and consumer’s protection.
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